logo
  Join        Login             Stock Quote

Optimer $19 A Share Buyout Rumours Swell (NASDAQ:OPTR) (NASDAQ:CLDA)

 March 24, 2011 10:49 AM
 


Popularity in equities has never been higher than in 2011, with most analysts, including Hilary Kramer raving about the S&P 500 (NYSE:SPY) namely due to $2 trillion dollars worth of cash lying around on the balance sheets of companies. This leads to mergers and acquisitions, along with consolidations which run up prices with the US treasury bond bubble which is deflating, leading to a flight to safety in equities. Despite Japan's unfortunate natural disaster, the rest of the world economy has really begun to firm up thus alleviating fear and paving the way for one of the strongest bull markets in history to commence.

Such was the case with AT&T's shocking buyout of T-Mobile (NYSE:T), a marriage that cost $39 billion dollars, helping boost markets and confidence around the world. And while this deal received front-page acclamation on just about every mainstream media outlet, smaller companies have been engaging in such activities as well, especially the biotech industry. During February, Clinical Data (NASDAQ:CLDA) won a surprising approval for its flagship product, viibryd,  the first antidepressant approved by the FDA in over 15 years, leading to Forest Labs (NYSE:FRX) sweeping in to buy the company for $1.2 billion. Forest's price reflects its interest in viibryd's claim that it is safer and triggers fewer sexual side effects than other SSRI drugs now on the market. The drug is being touted as the "first and only" antidepressant to combine an SSRI and a serotonin 1a receptor partial agonist in one molecule.

[Related -Is The S&P 500 Triple Top Actually A Bullish Sign?]

[Related -T-Mobile US Inc (NYSE:TMUS): AT&T Inc.(NYSE:T) Could Suffer In Wireless War]

This left many biotech bargain hunters looking for the next blockbuster buyout, which then leads to Optimer Pharmaceuticals. Much to the likes of Clinical Data's recently approved viibryd, Optimer's flagship product, fidaxomicin, has a higher safety profile, along with many other added benefits which could make it the first Clostridium defficile infection (CDI) treatment in more than 25 years. Currently, the infection only has two pharmacological options as treatments: metronidazole and oral vancomycin, both of which lack the ability to reduce recurrences, while improving global cure rates. This is where fidaxomicin comes in — it not only has a higher cure rate, but boasts a statistically significant reduction in recurrences and a substantially higher global cure rate. You may view the company CMO, Sherwood Gorbach discussing its advantages in a video here.

Fidaxomicin vs. Vancocin

  • Similarly high cure rates: The clinical cure rates between fidaxomicin and vancomycin were similar, with slightly better results from fidaxomicin.
  • Statistically Significant in Reducing Recurrences: fidaxomicin significantly reduced the risk of recurrence among CDI patients.
  • Substantial Improvement in Global Cure Rates: Compared to the current treatment, fidaxomicin demonstrated a statistically significant higher global cure rate, defined as curing the patient at the end
    of treatment without recurrence.

The following table outlines top-line data from two Phase 3 clinical trials of fidaxomicin that together enrolled 1,164 patients in the U.S., Canada and Europe.


Next Page >>123
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageShould You Invest In The Hottest New Trend In Finance?

Thanks to major changes in regulation, social media and technology, the business of banking has undergone read on...

article imageStrong Attractor in Action Pulling S&P 500 Down

The attractor is formed by the 200-day moving average and the 50% Fibonacci retracement of the up move from read on...

article imageIs The Weak Housing Market A Warning Sign For The US Economy?

Today’s US economic releases – housing starts and business survey data for the manufacturing sector – read on...

article imageShort-term Pullback or Something Worse?

A few weeks ago when we called for a short-term pullback of 4 to 5%, it was due solely to the short-term read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.